<DOC>
	<DOCNO>NCT00147732</DOCNO>
	<brief_summary>TITLE : A multicentre , randomise , phase III clinical trial comparing accelerate radiotherapy accelerate radiotherapy plus carbogen nicotinamide ( ARCON ) clinical stage T2-4 laryngeal carcinoma . PRIMARY OBJECTIVE : Does addition carbogen nicotinamide schedule accelerate radiotherapy patient clinical stage T2-4 laryngeal carcinoma improve local primary tumour control ? Definitive analysis perform local control rate two year completion radiotherapy . SECONDARY OBJECTIVES : Does addition carbogen nicotinamide - increase larynx preservation rate ? - increase regional control rate ? - increase toxicity accelerate radiotherapy ? - improve overall quality life ? - improve disease-free survival ? - improve overall survival ? STUDY DESIGN : An open-label , randomised clinical trial assign patient 1:1 ratio one follow treatment arm : - accelerate radiotherapy - accelerate radiotherapy plus carbogen nicotinamide PATIENT CHARACTERISTICS AND NUMBER : 344 patient clinical T2-4 laryngeal carcinoma MEASUREMENTS : - time local failure - time regional failure - survival functional larynx - overall disease-free survival - frequency severity complication related radiotherapy carbogen nicotinamide - quality life assessment</brief_summary>
	<brief_title>Randomized Trial ARCON Larynx Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Pathological confirm squamous cell carcinoma larynx . TNMclassification ( UICC 1997 , appendix I ) : T34 glottic supraglottic carcinoma T2 glottic carcinoma impair cord mobility subglottic extension T2 supraglottic carcinoma invasion mucosa base tongue vallecula invasion medial wall piriform sinus . Nstage , M0 . WHO performance status 0 1 ( appendix II ) . Age &gt; 18 year . Written informed consent . Quality life questionnaire complete . Prior concurrent treatment tumour . Severe stridor adequate debulking airway possible . Impaired renal function : serum creatinine upper normal limit . Use nefrotoxic medication ( include ACEinhibitors ) discontinue duration radiation treatment . Impaired hepatic function : ASAT ALAT 1.5 time upper normal limit . Use anticonvulsants discontinue duration radiation treatment . History malignancy previous 5 year except basal cell carcinoma skin , carcinoma situ cervix , superficial bladder neoplasm ( pTa ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>larynx carcinoma</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>carbogen</keyword>
	<keyword>nicotinamide</keyword>
</DOC>